The blockade of the PD-1/PD-L1 axis with monoclonal antibodies has revolutionized cancer therapy [4], particularly in melanoma [5], non-small cell lung carcinoma [6], and renal cell carcinoma [7]. This evidence concerns the gene CD274 and melanoma.